Meiji Yasuda Asset Management Co Ltd. Trims Stock Holdings in Insulet Corporation $PODD

Meiji Yasuda Asset Management Co Ltd. decreased its holdings in Insulet Corporation (NASDAQ:PODD) by 4.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,901 shares of the medical instruments supplier’s stock after selling 896 shares during the period. Meiji Yasuda Asset Management Co Ltd.’s holdings in Insulet were worth $4,964,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Larson Financial Group LLC grew its stake in Insulet by 426.3% during the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 81 shares in the last quarter. Zions Bancorporation National Association UT purchased a new position in Insulet during the first quarter valued at approximately $26,000. SouthState Corp grew its stake in Insulet by 253.3% during the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 76 shares in the last quarter. Ramirez Asset Management Inc. purchased a new position in Insulet during the first quarter valued at approximately $53,000. Finally, NewEdge Advisors LLC grew its stake in Insulet by 44.8% during the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock valued at $54,000 after acquiring an additional 64 shares in the last quarter.

Insulet Price Performance

PODD stock opened at $349.56 on Tuesday. The stock has a market cap of $24.61 billion, a PE ratio of 106.25, a P/E/G ratio of 2.92 and a beta of 1.36. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. Insulet Corporation has a one year low of $216.00 and a one year high of $350.00. The firm has a 50 day simple moving average of $308.26 and a two-hundred day simple moving average of $290.34.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. The firm had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business’s quarterly revenue was up 32.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, analysts predict that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on PODD shares. Wolfe Research raised shares of Insulet from a “peer perform” rating to an “outperform” rating and set a $350.00 price objective for the company in a research note on Tuesday, May 13th. The Goldman Sachs Group initiated coverage on shares of Insulet in a research note on Friday, May 30th. They set a “buy” rating and a $380.00 price objective for the company. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Insulet in a research note on Friday, May 16th. Canaccord Genuity Group boosted their price target on shares of Insulet from $331.00 to $353.00 and gave the stock a “buy” rating in a research note on Friday, August 8th. Finally, Citigroup reissued a “buy” rating on shares of Insulet in a research note on Tuesday, July 8th. Sixteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $335.12.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.